Killingworth, CT, United States of America

Kevin J Hodgetts

This inventor holds 18 USPTO granted patents and 6 published patent applications, plus 1 CIPO patent and 1 EPO patent, primarily in Pharmaceutical Chemistry. Top assignees: Neurogen Corporation, Pfizer Corporation, Other. Active years: 2001-2011.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Kevin J Hodgetts. Retrieved from https://idiyas.com/inventor/kevin-j-hodgetts

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 18 (Patent Applications = 6)

% Patents Active = 33.3

CIPO Patents = 1

EPO Patents = 1 (Patent Applications = 4)

Average Co-Inventor Count = 5.1

ph-index = 5

Forward Citations = 275(Granted Patents)

Location History:

Branford, CT (US) (2001 - 2002)
Killingworth, CA (US) (2006)
Kilingworth, CT (US) (2007)
Killingworth, CT (US) (2002 - 2011)

Company Filing History:

2 out of 834,659

Other

patents

where one patent can have more than one assignee

Years Active: 2001-2011

Loading Chart...

Areas of Expertise:

Quinolin-4-Ylamine

Capsaicin Receptor Modulators

Arylpyrazines

Quinazolin-4-Ylamine

Heterocycles

Bradykinin B2 Receptors

Imidazopyridines

Piperazines

Pharmaceutical Chemistry

Selective Modulators

Analogues

Substituted Compounds

18 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 7935702 - Substituted biaryl quinolin-4-ylamine analogues (2011-05-03),

2. 7488740 - Substituted quinolin-4-ylamine analogues (2009-02-10),

3. 7432275 - Carboxylic acid, phosphate or phosphonate substituted quinazolin-4-ylamine analogues as capsaicin receptor modulators (2008-10-07),

4. 7304059 - Substituted quinazolin-4-ylamine analogues (2007-12-04),

5. 7202250 - Substituted arylpyrazines (2007-04-10),

6. 7179807 - 5-substituted-2-arylpyrazines (2007-02-20),

7. 7169790 - 5-substituted 2-aryl-4-pyrimidinones (2007-01-30),

8. 7074929 - Certain alkylene diamine-substituted heterocycles (2006-07-11),

9. 7074799 - Substituted quinazolin-4-ylamine analogues (2006-07-11),

10. 6995161 - Substituted arylpyrazines (2006-02-07),

11. 6943173 - 5-substituted 2-aryl-4-pyrimidinones (2005-09-13),

12. 6723730 - Capsaicin receptor ligands (2004-04-20),

13. 6696445 - Certain alkylene diamine-substituted heterocycles (2004-02-24),

14. 6509366 - Substituted imidazoles as selective modulators of Bradykinin B2 receptors (2003-01-21),

15. 6506762 - Certain alkylene diamine-substituted heterocycles (2003-01-14),

Title: **Innovative Contributions of Kevin J Hodgetts**

Introduction

Kevin J Hodgetts is a prominent inventor based in Killingworth, Connecticut, USA. With an impressive portfolio of 18 patents, he has made significant contributions to the field of pharmaceuticals and receptor modulation. His innovative work has potential applications in both human medicine and veterinary science.

Latest Patents

Among Hodgetts' latest patents are the **Substituted Biaryl Quinolin-4-Ylamine Analogues**. These compounds serve as ligands that can modulate specific receptor activity both in vivo and in vitro. They are particularly beneficial for addressing conditions associated with pathological receptor activation in humans, domesticated companion animals, and livestock animals. In addition to this, he has also developed **Substituted Quinolin-4-Ylamine Analogues**, which share similar properties and applications in pharmaceutical compositions, providing methods for treating various disorders and conducting receptor localization studies.

Career Highlights

Hodgetts has significantly impacted the pharmaceutical industry during his career, particularly through his association with Neurogen Corporation, where he honed his skills in drug development and receptor biology. His work has aided in advancing understanding and treatment options within these medical fields.

Collaborations

Collaboration is a key part of Hodgetts' success. He has worked alongside notable colleagues such as Raymond F Horvath and Rajagopal Bakthavatchalam. Together, they have contributed to a collaborative environment that fosters innovation and advances in therapeutic research.

Conclusion

Kevin J Hodgetts exemplifies the spirit of innovation in the field of pharmaceuticals, as demonstrated by his extensive patent portfolio and collaborative efforts. His ongoing work continues to influence the landscape of receptor modulation and treatment options, showcasing the importance of inventors in advancing scientific and medical progress.

Profile summary based on public USPTO records.